Jason Bednar
Stock Analyst at Piper Sandler
(2.06)
# 3,057
Out of 5,044 analysts
183
Total ratings
37.14%
Success rate
-5.39%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICUI ICU Medical | Maintains: Overweight | $145 → $153 | $120.11 | +27.38% | 2 | Sep 10, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $105 → $83 | $71.75 | +15.68% | 14 | Aug 28, 2025 | |
| SOLV Solventum | Maintains: Overweight | $87 → $94 | $70.92 | +32.54% | 7 | Aug 8, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $185 → $200 | $184.21 | +8.57% | 10 | Aug 8, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $146.41 | +43.43% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $20.06 | -5.28% | 13 | Aug 1, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $110 → $105 | $82.75 | +26.89% | 13 | Jul 31, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $250 → $190 | $133.14 | +42.71% | 31 | Jul 31, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.98 | +26.26% | 12 | Jul 31, 2025 | |
| NVCR NovoCure | Reiterates: Overweight | $34 | $13.37 | +154.30% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $4.01 | -12.72% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $13.07 | +22.42% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $63.21 | +21.82% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $16.57 | -21.54% | 2 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $1.81 | +148.62% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $241.20 | +9.87% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $5.00 | +20.00% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.19 | +67.06% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $2.10 | +852.38% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $545.39 | -31.79% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $79.40 | +19.65% | 1 | Apr 19, 2023 |
ICU Medical
Sep 10, 2025
Maintains: Overweight
Price Target: $145 → $153
Current: $120.11
Upside: +27.38%
The Cooper Companies
Aug 28, 2025
Maintains: Overweight
Price Target: $105 → $83
Current: $71.75
Upside: +15.68%
Solventum
Aug 8, 2025
Maintains: Overweight
Price Target: $87 → $94
Current: $70.92
Upside: +32.54%
Becton, Dickinson and Company
Aug 8, 2025
Maintains: Neutral
Price Target: $185 → $200
Current: $184.21
Upside: +8.57%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $146.41
Upside: +43.43%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $20.06
Upside: -5.28%
Merit Medical Systems
Jul 31, 2025
Maintains: Overweight
Price Target: $110 → $105
Current: $82.75
Upside: +26.89%
Align Technology
Jul 31, 2025
Maintains: Overweight
Price Target: $250 → $190
Current: $133.14
Upside: +42.71%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.98
Upside: +26.26%
NovoCure
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $13.37
Upside: +154.30%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $4.01
Upside: -12.72%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $13.07
Upside: +22.42%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $63.21
Upside: +21.82%
Apr 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $16.57
Upside: -21.54%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.81
Upside: +148.62%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $241.20
Upside: +9.87%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $5.00
Upside: +20.00%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $4.19
Upside: +67.06%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $2.10
Upside: +852.38%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $545.39
Upside: -31.79%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $79.40
Upside: +19.65%